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Identity 
Other names: FLRG, FSRP 
HGNC (Hugo): FSTL3 
Location: 19p13.3 
Local order: RNF126 (ring finger protein 126) - 
FSTL3 - PRSSL1 (protease, serine-like 1). 
Note: The term follistatin-related protein has been used 
to refer to either FSTL3 (FSRP) or FSTL1 (FRP), 
which may cause some confusion. A search in 
MEDLINE for FSTL3 will also retrieve several reports 




The human FSTL3 gene is comprised of five exons 
spanning 7004 bp on chromosome 19p13 and gives rise 
to a main transcript of 2525 bp.  
The first exon encodes the signal peptide plus nine 
residues of the N-terminal domain, the second exon 
encodes the remainder of the N-terminal domain, the 
third and the fourth exon each code for a follistatin 
module and the fifth exon encodes the C-terminus rich 
in acidic amino acids (Schneyer et al., 2001; Sidis et 
al., 2002). 
 
Intron/exon structure of the FSTL3 gene and domain architecture of FSTL3 protein. 1,2,3,4,5: exon number; SP: signal peptide; 
NTD: N-terminal domain; FSD 1: follistatin domain 1; FSD 2: follistatin domain 2; AT: acidic tail. 
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Transcription 
Transcription of FSTL3 mRNA was shown to be 
stimulated by TGF beta and activin A via Smad 
proteins (Bartholin et al., 2001; Bartholin et al., 2002), 
which seems to be part of a negative feedback loop as 
FSTL3 can antagonize activin A (see below). In a 
different study it was found that GDF9 - another TGF 
beta superfamily cytokine - can suppress both basal and 
activin A-induced FSTL3 (and follistatin) mRNA and 
protein levels in cultured human granulosa-lutein 
(hGL) cells from women undergoing in vitro 
fertilization (IVF) treatment (Shi et al., 2011).  
In addition NF-kappaB responsive elements have been 
identified in the FSTL3 promoter and are involved in 
the cooperative stimulation of FSTL3 transcription by 
TNF alpha and TGF beta (Bartholin et al., 2007). 
Upregulation of FSTL3 mRNA was observed as a 
response to hypoxia in human trophoblasts and a role 
for hypoxia inducible factor (HIF1 alpha) was 
suggested. In another study a combination of 17 beta 
estradiol and progesterone, but not either factor alone, 
stimulated FSTL3 expression in cultured human 
endometrial stromal cells (Wang et al., 2003). An 
analysis of the murine FSTL3 promoter identified 
phorbol 12-myristate 13-acetate (PMA) but not cAMP 
as transcriptional activators. 
Protein 
Description 
The FSTL3 protein precursor consists of 263 amino 
acids. Amino acids 1-26 form the signal peptide, which 
is reponsible for directing the protein to the secretory 
pathway but not present in the mature secreted protein. 
FSTL3 has been described to contain 2 follistatin (FS) 
domains (aa 97-168 and 169-244) (Schneyer et al., 
2001) characterized by a conserved arrangement of 10 
cysteine residues. The FS domains also have similarity 
with the Kazal domains found in multiple serine 
protease inhibitors. The FSTL3 protein contains two 
potential N-glycosilation sites on asparagines 73 and 
215. Peptide N-glycosidase F digestion reduced the size 
of ectopically expressed FSTL3 from 33 to 27 kDa in 
Western analysis (Hayette et al., 1998). 
Expression 
FSTL3 is expressed in a wide variety of tissues and 
organs with the highest expression in placenta and 
testis and low to absent expression in the hematopoietic 
system (Hayette et al., 1998; Tortoriello et al., 2001). 
Localisation 
The signal peptide directs the nascent protein to the 
secretory pathway and FSTL3 has been detected in cell 
culture supernatants and in human serum (Hayette et 
al., 1998; Hill et al., 2002; Pryor-Koishi et al., 2007). In 
addition to its role as a secreted protein FSTL3 has also 
been found in the cell nucleus in a number of different 
cell lines, primary cells (Tortoriello et al., 2001) and 
tissue sections (Torres et al., 2007). Nuclear FSTL3 
was glycosylated, albeit to a lower degree than secreted 
FSTL3, suggesting that it enters the nucleus after 
partial processing in the ER (Saito et al., 2005). 
Function 
Similar to follistatin, secreted FSTL3 was shown to 
bind activin A and with lower affinity several other 
members of the TGF beta family including activin B, 
myostatin and BMP2, BMP6, and BMP7 (but 
excluding for instance TGF beta and BMP4) (Tsuchida 
et al., 2000; Tortoriello et al., 2001; Sidis et al., 2002; 
Hill et al., 2002; Schneyer et al., 2003). Affinity for 
BMPs, however, seems to be quite low and has been 
questioned by other studies (Sidis et al., 2006). FSTL3 
bound ligands are unable to activate their cognate 
receptors and thus FSTL3 blocks signal transduction. 
Structural and biochemical data have implicated the N-
terminal domain and the two FS domains in ligand 
binding and antagonism (Sidis et al., 2005; Stamler et 
al., 2008; Cash et al., 2012).  
In contrast to follistatin, FSTL3 does not contain a 
heparin binding motif and does not bind cell surface 
heparan-sulfate proteoglycans (Sidis et al., 2002).  
In addition to binding TGF beta family ligands, FSTL3 
was demonstrated to interact with ADAM12 (a 
disintegrin and metalloprotease 12), an extracellular 
protein that has been implicated in insulin-like growth 
factor (IGF) and epidermal growth factor (EGF) 
receptor signaling (Bartholin et al., 2005), as well as 
with fibronectin type 1, which could indicate a role of 
FSTL3 in cell adhesion (Maguer-Satta et al., 2006).  
Nuclear FSTL3 was shown to interact with AF10 
(ALL-1 fused gene from chromosome 10) enhancing 
its homo-oligomerization and transcriptional activity 
(Forissier et al., 2007). 
FSTL3 knock-out mice had increased pancreatic island 
number and size, enhanced insulin sensitivity and 
hepatic steatosis suggesting a role of FSTL3 in glucose 
and fat homeostasis (Mukherjee et al., 2007).  
Combined knockout of FSTL3 and follistatin, however, 
led to increased fat mass and insulin resistance despite 
elevated insulin production (Brown et al., 2011). 
Homology 
FSTL3 has a similar domain architecture as follistatin, 
but harbours only two instead of three follistatin 
modules (Tortoriello et al., 2001). Follistatin modules 
are found in varying numbers in a wider set of secreted 
proteins including FSTL1, SPARC/osteonectin, or 
agrin (Ullman and Perkins, 1997). With respect to 
activin binding ability, functional homology among 
follistatin domain-containing proteins has only been 
demonstrated for FSTL3 and follistatin (Tsuchida et al., 
2000). Between different species FSTL3 is clearly 
conserved (96% amino acid identity between mouse 
and rat and about 80% for either of these species 
compared to human), albeit to a lesser degree than 
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follistatin, which has around 97% amino acid identity 
between human, mouse and rat. 
Mutations 
Somatic 
A t(11;19)(q13;p13) translocation has been described in 
a case of B-cell chronic lymphocytic leukemia.  
The chromosomal breakpoint occurred about 7 kbp 
upstream of FSTL3 leading to ectopic expression of the 
complete FSTL3 protein, likely as a consequence of 
altered upstream cis-regulatory sequences (Hayette et 
al., 1998).  
In the same study structural rearrangement of the 
FSTL3 locus has also been described in a case of non-
Hodgkin lymphoma.  
A deletion of about 1.2 Mb on chromosome 19p13.3 
was identified in a patient with cleft palate, hearing 
impairment, congenital heart malformation, keloid 
scarring, immune dysregulation, and mild learning 
difficulties. The deleted area encompasses about 60 
genes including FSTL3 (Archer et al., 2005). 
Implicated in 
Malignant blood disorders 
Disease 
Structural rearrangement of the FSTL3 locus has been 
described in malignant blood disorders (see above) and 
it has been suggested that deregulated expression of 




High expression of FSTL3 was observed in invasive 
breast carcinoma compared to normal luminal epithelial 
cells.  
SiRNA-mediated knock-down of FSTL3 expression in 
breast cancer cell lines lead to growth inhibition, smad2 
phosphorylation and increased transcription of activin 
target genes (Razanajaona et al., 2007). These 
observations suggest that FSTL3 may contribute to 
tumorigenesis by antagonizing growth limiting activin 
effects.  
In agreement with this notion another study reported 
increased FSTL3 mRNA and protein levels in the 
epithelial compartment in infiltrating ductal carcinoma 
of the breast when compared to normal breast tissue 
(Bloise et al., 2009). 
Hepatocellular carcinoma 
Disease 
FSTL3 expression levels were increased in hepatocytes 
in chemical hepatocarcinogenesis models in the rat but 
decreased in hepatocellular carcinoma (HCC) in 
humans (Grusch et al., 2006). 
Endometrial adenocarcinoma 
Disease 
Downregulation of FSTL3 expression was found in 




Ovarian endometriotic lesions showed a deranged 
expression of FSTL3 as well as follistatin. While 
follistatin expression was increased, FSTL3 mRNA and 
protein expression were lower in ovarian endometriosis 




The mRNA and protein levels of FSTL3 were 
compared in placentas and maternal sera of women 
with uncomplicated pregnancy and those with pre-
eclampsia.  
FSTL3 was upregulated in syncytiotrophoblast cells of 
pre-eclamptic placental tissue and in maternal serum. 
Its further evaluation as potential addition to existing 
diagnostic markers of pre-eclampsia was suggested 
(Pryor-Koishi et al., 2007). 
Heart disease 
Disease 
FSTL3 (and FSTL1) were elevated in heart failure. 
FSTL3 expression correlated with markers of disease 
severity and returned to normal after recovery.  
The protein was localized to myocytes and endothelium 
and the expression profile of FSTL3 on microarrays 
revealed an association with the nuclear compartment 
and with genes involved in signal transduction and 
transcription (Lara-Pezzi et al., 2008). In a mouse 
model activin A and FSTL3 were upregulated in the 
herat by ischemic injury. While activin A protected 
myocytes from cell death, this effect was antagonized 
by FSTL3 (Oshima et al., 2009). 
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